Impax Laboratories and Perrigo have entered into a collaboration for the development, manufacture and commercialization of an undisclosed extended topical generic drug product. Financial terms were not disclosed.
“We are excited to expand our relationship with Perrigo on this product,” said Larry Hsu, Ph.D., president and chief executive officer of Impax Laboratories. In just over two years, Impax has partnered with four different companies on 27 alternative dosage form products, with 18 of these either pending approval at the U.S. Food and Drug Administration or under development. We will continue to focus on delivering growth from high-value products, technologies, and businesses in complementary dosage forms.”
Perrigo’s chairman, president and chief executive officer Joseph C. Papa, said, “This collaboration is yet another example of our long-term investment in development of products in the extended topical space. We are pleased to be partnering with Impax on this opportunity to be first to market with this important new product, making quality healthcare more affordable for our customers as quickly as possible.”